

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

SCHEDULE 13G/A\*

Under the Securities Exchange Act of 1934

(Amendment No. 1)\*

**NeoGenomics, Inc.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**64049M209**

(CUSIP Number)

**December 31, 2013**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)  
☐ Rule 13d-1(c)  
☒ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.: 64049M209

1 Names of Reporting Persons:  
Abbott Laboratories

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  
(b) ☐

3 SEC Use Only

4 Citizenship or Place of Organization:  
State of Illinois

5 Sole Voting Power:  
865,558

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

6 Shared Voting Power:  
0

7 Sole Dispositive Power:  
865,558

8 Shared Dispositive Power:  
0

9	Aggregate Amount Beneficially Owned by Each Reporting Person: 865,558
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9: 1.7
12	Type of Reporting Person (See Instructions): CO

2

<b>Item 1(a).</b>	Name of Issuer: NeoGenomics, Inc.
<b>Item 1(b).</b>	Address of Issuer's Principal Executive Offices: 12701 Commonwealth Drive, Suite 9 Fort Myers, Florida 33913
<b>Item 2(a).</b>	Name of Person Filing: Abbott Laboratories
<b>Item 2(b).</b>	Address of Principal Business Office or, if none, Residence: 100 Abbott Park Road Dept. 322, Bldg. AP6A-2 Abbott Park, Illinois 60064-6049
<b>Item 2(c).</b>	Citizenship: Not applicable.
<b>Item 2(d).</b>	Title of Class of Securities: Common Stock
<b>Item 2(e).</b>	CUSIP Number: 64049M209

<b>Item 3.</b>	<b>If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:</b>
(a)	<input type="radio"/> Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	<input type="radio"/> Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	<input type="radio"/> Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	<input type="radio"/> Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
(e)	<input type="radio"/> An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	<input type="radio"/> An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	<input type="radio"/> A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)	<input type="radio"/> A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	<input type="radio"/> A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	<input type="radio"/> A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); and
(k)	<input type="radio"/> Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: _____.

3

<b>Item 4.</b>	<b>Ownership.</b>
Item 4(a)	Amount beneficially owned:

865,558 shares

Item 4(b) Percent of class:  
1.7%.

Item 4(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote:  
865,558 shares.

(ii) Shared power to vote or to direct the vote:  
0.

(iii) Sole power to dispose or to direct the disposition of:  
865,558 shares.

(iv) Shared power to dispose or to direct the disposition of:  
0.

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. x

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the parent Holding Company or Control Person.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

4

**Item 10. Certifications.**

Not applicable.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2014

**ABBOTT LABORATORIES**

By: /s/ Thomas C. Freyman  
Name: Thomas C. Freyman  
Title: Executive Vice President, Finance and  
Chief Financial Officer

5